The US Food and Drug Administration (FDA) has provided Emergency Use Authorisation (EUA) to PerkinElmer for its New Coronavirus RT-PCR test. Laboratories certified under Clinical Laboratory Improvement Amendments (CLIA) can immediately begin using the test to detect the virus that causes Covid-19.
Perkin Elmer’s RT-PCR test is an in vitro diagnostic that is available in over 30 countries worldwide.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
PerkinElmer CEO Prahlad Singh said: “Despite the challenging environment, our employees have demonstrated unwavering commitment over the past two months to combat this global pandemic. The breadth of PerkinElmer’s total workflow solution puts us in a unique position to rapidly address the needs of our clinical diagnostics customers.”
